Skip to Main Content

Paper Details

Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma.
Cancer Cell
237
2021
ICB, Macrophages, PBRM1, PBRM1 mutation, RCC, advanced RCC, advanced renal cell carcinoma, cancer, cancer and, cancer and immune cells, cancer cell subpopulations, cancer cells, cytotoxic T cells, immune cell populations, interferon, metastatic RCC, patients, single-cell transcriptomes
Author NameAffiliation
Michael S CuocoBroad Institute of Harvard and MIT
Alok K TewariDana-Farber Cancer Institute, USA Harvard Medical School
Jihye ParkDana-Farber Cancer Institute, USA Broad Institute of Harvard and MIT
Jihye ParkDana-Farber Cancer Institute, USA Broad Institute of Harvard and MIT
Orit Rozenblatt-RosenBroad Institute of Harvard and MIT
Aviv RegevBroad Institute of Harvard and MIT, USA Howard Hughes Medical Institute and Koch Institute for Integrative Cancer Research
Aviv RegevBroad Institute of Harvard and MIT, USA Howard Hughes Medical Institute and Koch Institute for Integrative Cancer Research
Toni K ChoueiriDana-Farber Cancer Institute, USA Harvard Medical School
Eliezer M Van AllenDana-Farber Cancer Institute, USA Center for Cancer Genomics, USA Broad Institute of Harvard and MIT
Eliezer M Van AllenDana-Farber Cancer Institute, USA Center for Cancer Genomics, USA Broad Institute of Harvard and MIT
  • 1 - 10

Datasets

Release 1.2